ArticleThe Journal of clinical investigation2006
Identification and characterization of noncalcemic, tissue-selective, nonsecosteroidal vitamin D receptor modulators.
Article in The Journal of clinical investigation, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 118 citations in OpenAlex.
- Response of Vitamin D Concentration to Vitamin D3 Administration in Older Adults without Sun Exposure: A Randomized Double-Blind Trial.Journal of the American Geriatrics Society · 2016Trial
- Light-Regulated Agonists Spatiotemporally Activating the Vitamin D Receptor Mitigate Psoriasis-like Inflammation in Mice without Inducing Hypercalcemia.ACS central science · 2025Article
- Hyperagonism of a Vitamin D Receptor Agonist/Histone Deacetylase Inhibitor Hybrid Molecule.Journal of medicinal chemistry · 2025Article
- The Role of Vitamin D Metabolism-Related Genes in Recurrent Pregnancy Loss and Their Immune Microenvironmental Changes.Journal of multidisciplinary healthcare · 2025Article
- Comparative Analyses of the Safety Profiles of Vitamin D Receptor Agonists: A Pharmacovigilance Study Based on the EudraVigilance Database.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Is There a Role of Vitamin D in Alzheimer's Disease?CNS & neurological disorders drug targets · 2024Review
- Effect of Calcitriol and Vitamin D Receptor Modulator 2 on Recovery of Injured Skeletal Muscle in Wistar Rats.Biomedicines · 2023Article
- Brain nuclear receptors and cardiovascular function.Cell & bioscience · 2023Review
- Vitamin D in Neurological Diseases.International journal of molecular sciences · 2022Review
- Potential Role of Natural Products to Combat Radiotherapy and Their Future Perspectives.Molecules (Basel, Switzerland) · 2021Review
- Bile acids mediated potential functional interaction between FXR and FATP5 in the regulation of Lipid Metabolism.International journal of biological sciences · 2020Review
- Update on pharmacologically-relevant vitamin D analogues.British journal of clinical pharmacology · 2019Review
- Identification of Novel Non-secosteroidal Vitamin D Receptor Agonists with Potent Cardioprotective Effects and devoid of Hypercalcemia.Scientific reports · 2017Article
- Article
- Vitamin D metabolism, mechanism of action, and clinical applications.Chemistry & biology · 2014Review
- The application of the open pharmacological concepts triple store (open PHACTS) to support drug discovery research.PloS one · 2014Article
- Nuclear receptors and their selective pharmacologic modulators.Pharmacological reviews · 2013Review
- Nuclear receptors in bone physiology and diseases.Physiological reviews · 2013Review
- Natural compounds as anticancer agents: Experimental evidence.World journal of experimental medicine · 2012Review
- A Nonsecosteroidal Vitamin D Receptor Modulator Ameliorates Experimental Autoimmune Encephalomyelitis without Causing Hypercalcemia.Autoimmune diseases · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vitamin D receptor (VDR) ligands are therapeutic agents for the treatment of psoriasis, osteoporosis, and secondary hyperparathyroidism. VDR ligands also show immense potential as therapeutic agents for autoimmune diseases and cancers of skin, prostate, colon, and breast as well as leukemia. However, the major side effect of VDR ligands that limits their expanded use and clinical development is hypercalcemia that develops as a result of the action of these compounds mainly on intestine. In order to discover VDR ligands with less hypercalcemia liability, we sought to identify tissue-selective VDR modulators (VDRMs) that act as agonists in some cell types and lack activity in others. Here, we describe LY2108491 and LY2109866 as nonsecosteroidal VDRMs that function as potent agonists in keratinocytes, osteoblasts, and peripheral blood mononuclear cells but show poor activity in intestinal cells. Finally, these nonsecosteroidal VDRMs were less calcemic in vivo, and LY2108491 exhibited more than 270-fold improved therapeutic index over the naturally occurring VDR ligand 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3] in an in vivo preclinical surrogate model of psoriasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.